EAA-Guided AN69-oXiris and PMX-HP Therapy in Septic Patients
Key facts
- Who runs it
- Kyoung Moo Im
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 50 people, planned
- Started
- 11 Aug 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Adsorptive Hemofilter for Continuous Renal Replacement Therapy
- Polymyxin B-Immobilized Hemoperfusion Cartridge
- Record updated
- 26 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Participants must meet all of the following criteria:; Adults aged 18 years or older; Diagnosis of sepsis or septic shock caused by an intra-abdominal infection, including peritonitis, according to the Sepsis-3 criteria; Completion of emergency surgery for infection source control, with successful surgical control of the infection source; Admission to the surgical intensive care unit (SICU) for postoperative intensive care; Ability to undergo measurement of endotoxin activity (EA) using the Endotoxin Activity Assay (EAA); Determination by a critical care specialist that extracorporeal blood purification therapy with either AN69-oXiris or PMX-HP is clinically indicated; Ability to obtain central venous access and undergo extracorporeal blood purification therapy; Provision of voluntary written informed consent by the participant or the participant's legally authorized representative after receiving sufficient information about the study
Who cannot take part
- Participants meeting any of the following criteria will be excluded:; Younger than 18 years of age; Surgical source control of the infection was not performed or was considered incomplete; Pregnant or breastfeeding; Refusal to participate in the study or inability to obtain informed consent from a legally authorized representative; Concurrent participation in another clinical study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis and septic shock are life-threatening conditions in which the body's response to infection can cause dangerously low blood pressure and organ failure. In some patients with an infection inside the abdomen, severe inflammation may continue even after emergency surgery or another procedure has controlled the source of infection. Endotoxin is a substance produced by certain bacteria that may worsen this inflammation. The Endotoxin Activity Assay is a blood test that estimates how strongly endotoxin is affecting the body.
Read full original descriptionShow less
This study will compare two blood purification treatments, AN69-oXiris and polymyxin B hemoperfusion (PMX-HP), in patients receiving intensive care for sepsis or septic shock caused by an intra-abdominal infection. Blood purification removes blood through a central venous catheter, passes it through a special filter or cartridge, and then returns it to the body. These treatments are intended to reduce endotoxin or other substances involved in inflammation.
The study plans to enroll 50 participants at Seoul St. Mary's Hospital. Participants will be assigned by chance, in a 1:1 ratio, to receive either AN69-oXiris or PMX-HP. Participants and the clinical team will know which treatment is used.
The 2 groups in the trial
- AN69-oXirisTreatment being tested
Participants assigned to this arm will receive extracorporeal blood purification using an AN69-oXiris hemofilter through a central venous catheter. Treatment will be administered in sequential cycles during the 72-hour study period, with filter replacement according to the study protocol and the participant's clinical condition. Standard treatment for sepsis or septic shock will continue as clinically indicated.
Treatment: Adsorptive Hemofilter for Continuous Renal Replacement Therapy
- PMX-HPTreatment being tested
Participants assigned to this arm will receive direct hemoperfusion using a PMX-HP cartridge containing polymyxin B-immobilized fibers through a central venous catheter. Treatment will consist of one or two sessions. When a second session is administered, it will begin approximately 24 hours after initiation of the first session. Standard treatment for sepsis or septic shock will continue as clinically indicated.
Treatment: Polymyxin B-Immobilized Hemoperfusion Cartridge
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Establishing Evidence Based Application of AN69-oXiris and PMX-HP Therapies Based on the Endotoxin Activity Assay in Septic Patients
- Record updated
- 26 August 2026